202 related articles for article (PubMed ID: 32142590)
1. Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report.
Morikawa K; Kida H; Handa H; Inoue T; Miyazawa T; Mineshita M
Thorac Cancer; 2020 May; 11(5):1339-1343. PubMed ID: 32142590
[TBL] [Abstract][Full Text] [Related]
2. Histologic transformation of lung cancer during pembrolizumab therapy: A case report.
Si X; You Y; Zhang X; Wang H; Wang M; Zhang L
Thorac Cancer; 2020 Mar; 11(3):793-796. PubMed ID: 31944570
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Fiorelli A; Perrotta F; Mollica M; Santini M; Vitiello F; Gilli M; Calabrese C; Bianco A
J Cardiothorac Surg; 2019 Mar; 14(1):50. PubMed ID: 30832704
[TBL] [Abstract][Full Text] [Related]
5. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
8. [An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].
Sazuka M; Murano Y; Takada K; Nonaka K; Yamada H; Yamamoto H
Nihon Ronen Igakkai Zasshi; 2018; 55(4):679-685. PubMed ID: 30542036
[TBL] [Abstract][Full Text] [Related]
9. [A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Sakaguchi K; Kosaka M; Yamazaki Y
Gan To Kagaku Ryoho; 2020 May; 47(5):819-821. PubMed ID: 32408327
[TBL] [Abstract][Full Text] [Related]
10. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H
BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
Ueki Y; Suzuki M; Horikawa Y; Watanabe H; Yamaguchi Y; Morita C; Tsukada A; Takumida H; Kusaba Y; Katsuno T; Tsujimoto Y; Sakamoto K; Hashimoto M; Terada J; Ishii S; Takasaki J; Naka G; Iikura M; Izumi S; Takeda Y; Hojo M; Sugiyama H
Thorac Cancer; 2020 Sep; 11(9):2731-2735. PubMed ID: 32767641
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Zhou K; Jiang C; Li Q
Lung Cancer; 2019 Oct; 136():98-101. PubMed ID: 31476529
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
[No Abstract] [Full Text] [Related]
17. Successful treatment of two patients with unresectable lung squamous cell carcinoma with tislelizumab regardless of programmed death-ligand 1 expression: a report of two cases.
Wu Q; Cao Y; Li Y; Jiang N; Dong H; Dong Y; Chen F; Yue G; Luo Q
Anticancer Drugs; 2022 Jan; 33(1):e828-e833. PubMed ID: 34459453
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
19. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
